TY  - GEN
AU  - Liu,Joyce F
AU  - Barry,William T
AU  - Birrer,Michael
AU  - Lee,Jung-Min
AU  - Buckanovich,Ronald J
AU  - Fleming,Gini F
AU  - Rimel,Bj
AU  - Buss,Mary K
AU  - Nattam,Sreenivasa
AU  - Hurteau,Jean
AU  - Luo,Weixiu
AU  - Quy,Philippa
AU  - Whalen,Christin
AU  - Obermayer,Lisa
AU  - Lee,Hang
AU  - Winer,Eric P
AU  - Kohn,Elise C
AU  - Ivy,S Percy
AU  - Matulonis,Ursula A
TI  - Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
SN  - 1474-5488
PY  - 2015///0127
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Carcinoma, Ovarian Epithelial
KW  - Cisplatin
KW  - administration & dosage
KW  - Confidence Intervals
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Drug Administration Schedule
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Maximum Tolerated Dose
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - drug therapy
KW  - Neoplasms, Glandular and Epithelial
KW  - Ovarian Neoplasms
KW  - Phthalazines
KW  - Piperazines
KW  - Quinazolines
KW  - Risk Assessment
KW  - Survival Analysis
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/S1470-2045(14)70391-2
ER  -